Methoxyflurane


  • Methoxyflurane was initially produced as a volatile anaesthetic agent, but fell out of favour owing to concerns about renal injury
  • Now licensed for and primarily used for analgesia and sedation


MAC Blood:gas coefficient Oil:gas coefficient Molecular weight Boiling point SVP at 20ºC Safe ppm
0.16% 12 0.16 167 - 3kPa 15


Uses

  • Analgesia
    • Burns dressing changes
    • Acute pain from trauma

  • Sedation
    • Colonoscopy
    • Dental extractions
    • Biopsies e.g. prostate, bone marrow

Presentation

  • Penthrox - single use "green whistle" containing 3ml of methoxyflurane (25 - 30min continuous use)
  • Delivers 0.2 - 0.7% methoxyflurane which causes analgesia within a few breaths
  • Max 6ml/24hrs and maximum 15ml per week

Respiratory

  • When used as an analgesic, does not cause undue respiratory depression

Cardiovascular

  • As an anaesthetic agent, demonstrated cardiovascular stability over halothane
  • Occasional bradycardia but no major adverse cardiovascular effects when used as an analgesic

Neurological

  • Analgesia; equi-analgesic to 25microgram fentanyl IV
  • Sedative effect limited by very slow onset
  • Can in theory called malignant hyperthermia
  • Self-limiting nausea, dizziness and drowsiness following inhaled uses

Nephrotoxicity

  • Causes a high-output acute renal failure
    • Precise mechanism unclear
    • Due to impaired renal tubular concentrating ability
    • Leads to excessive diuresis, thirst and severe hyponatraemia
    • Resistant to vasopressin
    • Contributes to prolonged hospital admission and poor long-term outcome
    • Majority recover full renal function

Hepatotoxicity

  • Rare; likely an idiosyncratic reaction as with other volatiles
  • Appears to cause a self-limiting transaminitis ± clinical features